Nantahala Capital Management LLC Raises Stake in COMPASS Pathways plc (NASDAQ:CMPS)

Nantahala Capital Management LLC lifted its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 400.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,000,000 shares of the company's stock after acquiring an additional 800,000 shares during the period. Nantahala Capital Management LLC owned 1.46% of COMPASS Pathways worth $3,780,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of COMPASS Pathways in the fourth quarter valued at approximately $41,000. Wealthfront Advisers LLC purchased a new position in COMPASS Pathways in the 4th quarter valued at approximately $43,000. Flagship Harbor Advisors LLC acquired a new position in shares of COMPASS Pathways in the fourth quarter worth $43,000. Conservest Capital Advisors Inc. increased its position in shares of COMPASS Pathways by 28.9% during the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company's stock worth $51,000 after acquiring an additional 3,000 shares during the period. Finally, Simplify Asset Management Inc. acquired a new stake in shares of COMPASS Pathways in the fourth quarter valued at $54,000. 46.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CMPS. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price target on shares of COMPASS Pathways in a research note on Wednesday, January 15th. HC Wainwright restated a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a report on Tuesday, March 4th. Canaccord Genuity Group lowered their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, February 28th. Finally, Stifel Nicolaus initiated coverage on COMPASS Pathways in a research note on Thursday, February 27th. They issued a "buy" rating and a $11.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways has a consensus rating of "Buy" and an average target price of $20.20.

COMPASS Pathways Stock Up 2.2 %

Shares of NASDAQ CMPS traded up $0.09 during mid-day trading on Friday, reaching $4.19. The company had a trading volume of 630,372 shares, compared to its average volume of 797,755. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. The firm has a 50 day simple moving average of $3.34 and a two-hundred day simple moving average of $4.13. The stock has a market cap of $388.30 million, a P/E ratio of -1.90 and a beta of 2.34. COMPASS Pathways plc has a 52-week low of $2.49 and a 52-week high of $9.63.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). Sell-side analysts predict that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.